Michael Dabbah, MD
Orthopaedic Surgery of the Spine · Towson, MDNPI 1184673477
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $11,354 of the $13,018 with a category attached, or 87.2%. Stryker accounts for 87.5% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $10,831 and has fallen 98.4% since, to $174 in 2025.
Across 49 payments — averaging $265.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$11K
- Arthrex$541
- Abbott$366
- Medtronic$190
- Boston Scientific$140
- Supreme Orthopedic Systems, LLC$131
- plus $260 from 7 others
What the payments were for
- Royalty or licence$11,35487%
- Travel & lodging$5865%
- Food & beverage$1,0788%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 24 | $11,388 |
| Arthrex | 7 | $541 |
| Abbott | 3 | $366 |
| Medtronic | 4 | $190 |
| Boston Scientific | 2 | $140 |
| Supreme Orthopedic Systems, LLC | 2 | $131 |
| Globus Medical | 1 | $118 |
| Baxter Healthcare | 1 | $42 |
| Amgen | 1 | $26 |
| Radius Health, Inc. | 1 | $23 |
| Arteriocyte Medical Systems, Inc. | 1 | $20 |
| Native Surgical, LLC | 1 | $19 |
| Smith+Nephew | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,018 in reported general payments places this provider in the 60th percentile of 49 orthopaedic surgery of the spine providers in Maryland.
See all orthopaedic surgery of the spine providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 125 | $1,125 |
| Gabapentin | 64 | $565 |
| Methylprednisolone | 81 | $522 |
| Meloxicam | 122 | $318 |
| Cyclobenzaprine Hcl | 24 | $148 |
| Oxycodone Hcl | 25 | $142 |
| Tramadol Hcl | 46 | $133 |
| Mupirocin | 16 | $124 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery of the spine in Towson
- Ira FedderTowson$1.1M
- John CarboneBaltimore$25M
- Steven LudwigBaltimore$2.7M
- Joseph ObrienBethesda$2.4M
- Paul McAfeeBaltimore$2.2M
- Scott McGovernSalisbury$431K
- Amit JainBaltimore$250K
- Andrew MoOlney$166K
- Navinder SethiBethesda$114K
- Mesfin LemmaBaltimore$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.